相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Sangeetha Venugopal et al.
BLOOD CANCER JOURNAL (2022)
Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
Jan M. Middeke et al.
BLOOD ADVANCES (2022)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein et al.
BLOOD (2021)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
Courtney D. DiNardo et al.
LANCET ONCOLOGY (2021)
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
Giorgia Simonetti et al.
LEUKEMIA (2021)
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Almudena Aguilera-Diaz et al.
PLOS ONE (2020)
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Curtis Andrew Lachowiez et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The REDCap consortium: Building an international community of software platform partners
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2019)
IDH1-R132 changes vary according to NPM1 and other mutations status in AML
Brunangelo Falini et al.
LEUKEMIA (2019)
DH1R132, DH2R140 and 1DH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
Manja Meggendorfer et al.
LEUKEMIA (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The mechanisms of IDH mutations in tumorigenesis
Dan Ye et al.
CELL RESEARCH (2012)
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
Sadudee Chotirat et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission
W-C Chou et al.
LEUKEMIA (2012)
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
W-C Chou et al.
LEUKEMIA (2011)
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups
F. Damm et al.
LEUKEMIA (2011)
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
Saman Abbas et al.
BLOOD (2010)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Nicolas Boissel et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
